Lipoprotein distribution in the metabolic syndrome, type 2 diabetes mellitus, and familial combined hyperlipidemia
| Autor: | John D. Brunzell, Amir F Ayyobi |
|---|---|
| Rok vydání: | 2003 |
| Předmět: |
medicine.medical_specialty
Statin medicine.drug_class Lipoproteins Hyperlipidemia Familial Combined Hyperlipidemias Type 2 diabetes Niacin Insulin resistance Diabetes mellitus Internal medicine Abdomen Hyperlipidemia medicine Hyperinsulinemia Humans Hypolipidemic Agents Metabolic Syndrome business.industry nutritional and metabolic diseases Type 2 Diabetes Mellitus medicine.disease Thiazoles Endocrinology Adipose Tissue Diabetes Mellitus Type 2 Thiazolidinediones lipids (amino acids peptides and proteins) Hydroxymethylglutaryl-CoA Reductase Inhibitors Metabolic syndrome Cardiology and Cardiovascular Medicine business |
| Zdroj: | The American Journal of Cardiology. 92:27-33 |
| ISSN: | 0002-9149 |
| Popis: | Metabolic abnormalities associated with the metabolic syndrome are also present in patients with type 2 diabetes mellitus and in those with familial combined hyperlipidemia (FCHL). These abnormalities include central obesity, insulin resistance with hyperinsulinemia, hypertension, increased plasma triglycerides, and decreased high-density lipoprotein cholesterol levels. Other characteristics associated with FCHL include the presence of small, dense low-density lipoprotein cholesterol and increased apolipoprotein B. Patients with these abnormalities are at an increased risk for premature coronary artery disease. Treatment of the dyslipidemia associated with type 2 diabetes and FCHL with a combination of a statin and a thiazolidinedione or niacin offers the most comprehensive modality to correct the various lipid abnormalities. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect